Dymista: new intranasal rhinitis treatment

The nasal spray Dymista is now available for the treatment of perennial and seasonal allergic rhinitis.

Dymista is licensed for use in adults and children 12 years and older at a dose of one spray per nostril twice daily
Dymista is licensed for use in adults and children 12 years and older at a dose of one spray per nostril twice daily

PHARMACOLOGY

Dymista is a novel combination of two drugs in a nasal spray formulation: fluticasone propionate, a synthetic glucocorticoid, and azelastine, a potent selective H1-antagonist.1

CLINICAL STUDIES

Seasonal allergic rhinitis

The efficacy and safety of the fluticasone/azelastine combination spray in moderate to severe seasonal allergic rhinitis were assessed in 2 randomised, double-blind studies of similar design (n=610 and n=3398). Patients were randomised for twice-daily treatment with the combination nasal spray, fluticasone nasal spray, azelastine nasal spray or placebo (vehicle) for 14 days.2,3

In both studies, the reduction from baseline in total nasal symptom score (comprising nasal congestion, runny nose, itchy nose and sneezing) was significantly greater for the combination spray than for either agent used alone or placebo.2,3

Chronic rhinitis

A further study (n=612) evaluated the safety and efficacy of fluticasone/azelastine in patients with chronic rhinitis (including perennial allergic rhinitis and non-allergic rhinitis) over 12 months using fluticasone as an active control.4

The combination spray resulted in significantly greater nasal symptom relief than fluticasone monotherapy up to week 28. Treatment differences remained consistent to week 52 but significance could not be established owing to decreasing sample sizes.4

Adverse effect profile

The combination spray was well tolerated, with the most commonly reported adverse effects being epistaxis, dysgeusia, dysosmia and headache.1,3

References

  1. Dymista Summary of Product Characteristics, January 2013.
  2. Hampel F et al. Ann Allergy Asthma Immunol  2010; 105: 168–173.
  3. Carr W et al. J Allergy Clin Immunol 2012; 129: 12829.
  4. Price D et al.  Poster presented at Congress of European Academy of Allergy and Clinical Immunology. Geneva, Switzerland. June 2012. P32-872.

View Dymista drug record

Further information: Meda

Follow MIMS on Twitter

 

 


MIMS Clinics

Prescribing news and resources for key therapeutic areas, collated by the MIMS editors.

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS bulletins

News and updates straight to your inbox.

Prescribing Update: Fortnightly news bulletin
Alert:
Urgent prescribing updates
Spotlight: Disease-themed monthly round-up

Sign me up

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases

Promo Image

Clinical calculators

Handy calculators and conversions for primary care.